Melinda G Hollingshead

10PUBLICATIONS
89CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 17, 2026
Dynamic Switching of Apoptosis-Modulating Bim Heterodimers in Response to BH3 Mimetics in Xenograft Models of Hematologic Malignancies.

Jeevan Prasaad Govindharajulu, Sharon Fluss, Melinda G Hollingshead

|Feb 19, 2026
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Beverly A Teicher, Li Chen, Dianne L Newton

|Sep 17, 2025
RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Zahra Davoudi, Thomas S Dexheimer, Nathan P Coussens

|Jul 31, 2024
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.

Brian S White, Xing Yi Woo, Soner Koc

|Aug 18, 2022
3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor.

James L Tatum, Joseph D Kalen, Paula M Jacobs

|Apr 26, 2022
ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.

Melinda G Hollingshead, Nathaniel Greenberg, Michelle Gottholm-Ahalt

Pageof 2

Frequent Collaborators

8 joint publications

James H Doroshow

3 joint publications

Li Chen

2 joint publications

Shahanawaz Jiwani

2 joint publications

Thomas S Dexheimer